<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142854">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809184</url>
  </required_header>
  <id_info>
    <org_study_id>NN1956-4014</org_study_id>
    <secondary_id>2012-003048-66</secondary_id>
    <secondary_id>U1111-1132-1018</secondary_id>
    <nct_id>NCT01809184</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects</brief_title>
  <official_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this first human dose trial is to investigate
      the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body)
      and pharmacokinetic (exposure of the trial drug in the body) properties of NNC0148-0000-0287
      (insulin 287) in a GIPETÂ® I tablet formulation in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>As recorded from trial product administration and until completion of Sub-visit 2G (Day 13)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin concentration-time curve</measure>
    <time_frame>From 0 to 648 hours after a single dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate (GIR)-time curve</measure>
    <time_frame>From 0 to 24 hours after a single dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin 287</intervention_name>
    <description>Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral placebo adminstered corresponding to insulin 287 treatment</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 18.0-28.0 kg/m^2

          -  Subject who is considered to be healthy based on the medical history, physical
             examination, and the results of vital signs, electrocardiogram (ECG) and clinical
             laboratory tests performed during the screening visit, as judged by the investigator

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Previous participation in this trial. Participation is defined as randomised

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the
             investigator

          -  Any chronic disorder or severe disease which, in the opinion of the investigator,
             might jeopardise subject's safety or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Adrian</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
